[RandomLensman]

But these wouldn't be trials in a useful sense if patients can self-select. The economics might not pan out unless you get to gatekeeping similar to current trials.

And that assumes it would be all bona-fide substance providers.

[mortureb]

It could sure speed up a lot of the preclinical work to get to trials. I’m sure the company would love to not have to extrapolate their success probabilities based on mouse studies leading to extensive expensive trials that might not work out in the end.

[RandomLensman]

Doubt it as people would make very uninformed choices, thereby producing mostly worthless data.